Analysing MLPA Dosage Data

14
Analysing MLPA Dosage Data Andrew Wallace National Genetics Reference Laboratory (Manchester)

description

Analysing MLPA Dosage Data. Andrew Wallace National Genetics Reference Laboratory (Manchester). Problems with Dosage Analysis. Dosage data is quantitative – continuously variable Diagnostics requires a “binary” answer e.g. is the patient sample normal? Yes/No - PowerPoint PPT Presentation

Transcript of Analysing MLPA Dosage Data

Analysing MLPA Dosage Data

Andrew Wallace

National Genetics Reference Laboratory (Manchester)

Problems with Dosage Analysis

• Dosage data is quantitative – continuously variable

• Diagnostics requires a “binary” answer e.g. is the patient sample normal? Yes/No

• How can we analyse dosage data to provide the clear cut Yes/No answers we want?

Problems with Dosage Analysis

• Problem is compounded by the increasing numbers of analyses in newer tests e.g. MAPH and MLPA

WHY?• If we use a standard statistical measure of

significance for each exon tested the probability of a Type I error increases

• Alternatively if we use an arbitrary cut-offs we fail to take into account variabilities between loci

• Sample sizes limited to current experiment – too much variability between experiments

Dosage Quotient (DQ) Expectations

• We have one advantage - we know what results to expect i.e. for autosomal loci

• normal expect a DQ = 1.0• deleted then we expect a DQ = 0.5• duplicated then we expect a DQ = 1.5

Modified MLPA Dosage Analysis

• Used a small series of reference normal samples (5) run at the same time as experimental samples to determine DQ variability of each amplimer

• The deleted and duplicated values are inferred in relation to the control measurements (0.5x or 1.5x)

• Use the t statistic to estimate agreement with three hypotheses (i) deleted (ii) duplicated (iii) normal

• t statistic must be used rather than standard deviations due to small sample size

DQ likelihood distribution

1.0 1.1 1.2 1.30.90.8

0.7

DQ

Less variable

More variable

p

t-distributions of DQ values

0.5 1.0 1.5

0.5 1.0 1.5

Good quality data

Poorer quality data

p

p

n 2n 3n

n 2n 3n

Calculation of relative likelihood

0.5 1.0 1.5

p n 2n 3n

DQ = 0.9

p(2n) = 0.40

p(n) = 0.0009

p(3n) = 0.0006

Odds Norm:Del = 444:1

Odds Norm:Dup = 667:1

Good data – normal DQ

Calculation of relative likelihood

0.5 1.0 1.5

p n 2n 3n

DQ = 0.7

p(2n) = 0.0007

p(n) = 0.03

p(3n) = 0.00009

Odds Norm:Del = 1:42

Odds Norm:Dup = 7:1

Good data – deleted DQ

0.5 1.0 1.5

Calculation of relative likelihood

p n 2n 3n

DQ = 0.7

p(2n) = 0.007

p(n) = 0.021

p(3n) = 0.0007

Odds Norm:Del = 1:3

Odds Norm:Dup = 10:1

Poor data – ?deleted DQ

Good Quality Normal Data Showing Typical Variability

MLH1 Exon 5 – although prob of deviation from normal is low (1.2249%)

147356:1 Normal: Deleted - thus not Deleted

797:1 Normal:Duplicated - thus not Duplicated

Good Quality Data Giving an Unequivocal Odds Ratio for a Deletion

MSH2 Exon 4

1:12460 Normal:Deleted thus Deleted

3:1 Normal:Duplicated – can discard this hypothesis due to evidence for deletion

Poor Data Leading to Equivocal Odds Ratio

MLH1 Exon 9

3419:1 Normal: Deleted Thus Not deleted

3:1 Normal:Duplicated ?Normal

MLPA Dosage Analysis Spreadsheets

CONCLUSIONS• New analysis which can attach a meaningful

probability to dosage data – more objective• Unsuitable for detecting mosaic

deletions/duplications – will give equivocal odds ratios

• Can be applied to other quantitative PCR assays• Spreadsheets designed for BRCA1, HNPCC, VHL

and DMD available from me – eventually from NGRL website (www.ngrl.co.uk)